Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/2159-8290.CD-20-0941 http://scihub22266oqcxt.onion/10.1158/2159-8290.CD-20-0941 32699031!7541683!32699031     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 263.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 263.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 263.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 263.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 263.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 263.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cancer+Discov 2020 ; 10 (10): 1514-1527 Nephropedia Template TP {{tp|p=32699031|t=2020. Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study |pdf=|usr=}}{{32699031}} gab.com Text Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study JO: Cancer Discov http://www.kidney.de/pget.php?&tw=1&pmid=32699031 #FOAvip Among 2,186 U.S. adults with invasive cancer and laboratory-confirmed SARS-CoV-2 infection, we examined the association of COVID-19 treatments with 30-day all-cause mortality and factors associated with treatment. Logistic regression with multiple adjustments (e.g., comorbidities, cancer status, baseline COVID-19 severity) was performed. Hydroxychloroquine with any other drug was associated with increased mortality versus treatment with any COVID-19 treatment other than hydroxychloroquine or untreated controls; this association was not present with hydroxychloroquine alone. Remdesivir had numerically reduced mortality versus untreated controls that did not reach statistical significance. Baseline COVID-19 severity was strongly associated with receipt of any treatment. Black patients were approximately half as likely to receive remdesivir as white patients. Although observational studies can be limited by potential unmeasured confounding, our findings add to the emerging understanding of patterns of care for patients with cancer and COVID-19 and support evaluation of emerging treatments through inclusive prospective controlled trials. SIGNIFICANCE: Evaluating the potential role of COVID-19 treatments in patients with cancer in a large observational study, there was no statistically significant 30-day all-cause mortality benefit with hydroxychloroquine or high-dose corticosteroids alone or in combination; remdesivir showed potential benefit. Treatment receipt reflects clinical decision-making and suggests disparities in medication access.This article is highlighted in the In This Issue feature, p. 1426. Twit Text FOAVip Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study ????Cancer Discov http://www.kidney.de/pget.php?&tw=1&pmid=32699031 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32699031 #FOAvip English Wikipedia <ref>{{Cite pmid|32699031}}</ref> Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study #MMPMID32699031 Rivera DR; Peters S; Panagiotou OA; Shah DP; Kuderer NM; Hsu CY; Rubinstein SM; Lee BJ; Choueiri TK; de Lima Lopes G Jr; Grivas P; Painter CA; Rini BI; Thompson MA; Arcobello J; Bakouny Z; Doroshow DB; Egan PC; Farmakiotis D; Fecher LA; Friese CR; Galsky MD; Goel S; Gupta S; Halfdanarson TR; Halmos B; Hawley JE; Khaki AR; Lemmon CA; Mishra S; Olszewski AJ; Pennell NA; Puc MM; Revankar SG; Schapira L; Schmidt A; Schwartz GK; Shah SA; Wu JT; Xie Z; Yeh AC; Zhu H; Shyr Y; Lyman GH; Warner JL Cancer Discov 2020[Oct]; 10 (10): 1514-1527 PMID32699031show ga Among 2,186 U.S. adults with invasive cancer and laboratory-confirmed SARS-CoV-2 infection, we examined the association of COVID-19 treatments with 30-day all-cause mortality and factors associated with treatment. Logistic regression with multiple adjustments (e.g., comorbidities, cancer status, baseline COVID-19 severity) was performed. Hydroxychloroquine with any other drug was associated with increased mortality versus treatment with any COVID-19 treatment other than hydroxychloroquine or untreated controls; this association was not present with hydroxychloroquine alone. Remdesivir had numerically reduced mortality versus untreated controls that did not reach statistical significance. Baseline COVID-19 severity was strongly associated with receipt of any treatment. Black patients were approximately half as likely to receive remdesivir as white patients. Although observational studies can be limited by potential unmeasured confounding, our findings add to the emerging understanding of patterns of care for patients with cancer and COVID-19 and support evaluation of emerging treatments through inclusive prospective controlled trials. SIGNIFICANCE: Evaluating the potential role of COVID-19 treatments in patients with cancer in a large observational study, there was no statistically significant 30-day all-cause mortality benefit with hydroxychloroquine or high-dose corticosteroids alone or in combination; remdesivir showed potential benefit. Treatment receipt reflects clinical decision-making and suggests disparities in medication access.This article is highlighted in the In This Issue feature, p. 1426. |Adenosine Monophosphate/analogs & derivatives/therapeutic use[MESH] |Age Factors[MESH] |Aged[MESH] |Alanine/analogs & derivatives/therapeutic use[MESH] |Betacoronavirus/pathogenicity[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Clinical Decision-Making[MESH] |Coronavirus Infections/complications/diagnosis/*drug therapy/mortality[MESH] |Drug Therapy, Combination/methods/statistics & numerical data[MESH] |Drug Utilization/*statistics & numerical data[MESH] |Follow-Up Studies[MESH] |Glucocorticoids/therapeutic use[MESH] |Healthcare Disparities/*statistics & numerical data[MESH] |Hospital Mortality[MESH] |Humans[MESH] |Hydroxychloroquine/therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Neoplasms/complications/*mortality[MESH] |Pandemics[MESH] |Pneumonia, Viral/complications/diagnosis/*drug therapy/mortality[MESH] |Risk Factors[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH] |Sex Factors[MESH] |Treatment Outcome[MESH]Utilization of COVID-19 Treatments and Clinical Outcomes among Patient(epmc).pdf DeepDyve Pubget Overpricing